Janssen Biotech Inc. / Johnson & Johnson Innovation LLC / MD Anderson / /
Currency
USD / /
Event
M&A / Business Partnership / /
Facility
Research Institute of Texas / Memorial SloanKettering Cancer Center / /
IndustryTerm
Cancer Prevention / research protocols / social media entrepreneurs / /
MedicalCondition
cancers / late-stage melanoma / immunology-based cancer / cancer / lymphoma / tumors / gastric and prostate cancers / melanoma / breast cancer / /
MedicalTreatment
immunotherapy / /
Organization
Cancer Prevention and Research Institute of Texas / Memorial SloanKettering Cancer Center in New York / U.S. Food and Drug Administration / /
Person
Ferran Prat / Padmanee Sharma / Patrick Hwu / Jim Allison / Oncology / /
Position
scientific director / Economist / professor of Genitourinary Medical Oncology / vice president for strategic industry ventures / executive director of the immunotherapy platform / chair / co-director of the platform / Established Investigator / associate professor / /
Collaboration with Johnson & Johnson Innovation announced Tuesday, January 21, 2014 MD Anderson will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech Inc., to develop immunology-based